As of November 6, 2026, Evommune, Inc. is a publicly traded company (NYSE: EVMN). The largest holder reporting an active stake on Schedule 13D is LSP 7 Cooperatieve U.A., at 14.7%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Nan Fung Group Holdings Limited (10.9%), T. Rowe Price (5.4%), Point72 (5.3%) (Schedule 13D/A, February 19, 2026).
Is this your company?
About to sign with, pay or invest in Evommune, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Evommune, Inc. a real, registered company?
- Evommune, Inc. files with the SEC under CIK 2044725 (its SEC filings).
- Its shares are listed under the ticker EVMN on NYSE (SEC company record).
- Incorporated in Delaware; business address in Palo Alto, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Evommune, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-08-14).
Who are Evommune, Inc.'s owners and officers?
Evommune, Inc.: incorporated in Delaware; business address in Palo Alto, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-01-08)
- : Executive Officer, Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Director (Form D, 2025-01-08)
- : Executive Officer (Form D, 2025-01-08)
- : Executive Officer (Form D, 2025-01-08)
- : Executive Officer (Form D, 2025-01-08)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | T. Rowe Price Associates, Inc. | 5.4% |
| Schedule 13G/A, 2026-08-14 | Andera Partners | 3.9% |
| Schedule 13G, 2026-07-16 | Point72 Asset Management, L.P. | 5.3% |
| Schedule 13D/A, 2026-02-19 | Lsp 7 Cooperatieve U.A. | 14.7% |
| Schedule 13D/A, 2026-02-17 | Ra Capital Management, L.P. | 9.7% |
| Schedule 13G, 2026-02-13 | Nan Fung Group Holdings Limited | 10.9% |
| Schedule 13D, 2025-11-17 | Ra Capital Management, L.P. | 11% |
| Schedule 13G, 2025-11-17 | Andera Partners | 6% |
| Schedule 13D, 2025-11-14 | Lsp 7 Cooperatieve U.A. | 15.7% |
Questions about who owns Evommune, Inc.
Who owns Evommune, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Evommune, Inc.: Lsp 7 Cooperatieve U.A. (14.7%, Schedule 13D/A, filed 2026-02-19), Nan Fung Group Holdings Limited (10.9%, Schedule 13G, filed 2026-02-13), Ra Capital Management, L.P. (9.7%, Schedule 13D/A, filed 2026-02-17), T. Rowe Price Associates, Inc. (5.4%, Schedule 13G, filed 2026-08-14) and Point72 Asset Management, L.P. (5.3%, Schedule 13G, filed 2026-07-16).
Who are the largest shareholders of Evommune, Inc.?
By the share each holder's latest filing reports, the largest holders of Evommune, Inc. on this page are Lsp 7 Cooperatieve U.A. (14.7%), Nan Fung Group Holdings Limited (10.9%) and Ra Capital Management, L.P. (9.7%).
When did Lsp 7 Cooperatieve U.A. buy into Evommune, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Lsp 7 Cooperatieve U.A. on this page is the Schedule 13D, filed 2025-11-14, reporting 15.7%; its latest, Schedule 13D/A filed 2026-02-19, reports 14.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Evommune, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Evommune, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evommune, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
22 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Evommune, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director and 10% owner: 5,288,313 shares (14.6% of shares outstanding), held indirectly through a lsp 7 cooperatief u.a. (Form 4, 2026-02-18).
- LSP 7 Cooperative UA, a director and 10% owner: 5,288,313 shares (14.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-02-19).
- , a director and 10% owner: 3,372,001 shares (9.3% of shares outstanding), held indirectly through By Pivotal bioVenture Partners Fund I, L.P. and 1 other (Form 4, 2025-12-22).
- RA Capital, a director: 2,710,293 shares (7.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-02-17).
- RA Capital Healthcare Fund LP, a director: 2,710,293 shares (7.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-02-17).
Shares outstanding: 36,292,113 as of 2026-08-04, from the company's latest SEC cover page.
How much has Evommune, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-01-08 | $115.50M | $115.50M |
| Form D, 2025-01-08 | $81.80M | $84.45M |
| Form D, 2025-01-08 | $57.50M | $57.50M |
| Form D, 2025-01-07 | $12.46M | $12.46M |
Latest IPO step: Evommune, Inc. filed to go public (S-1, 2026-04-17).
IPO filings: S-1, 2026-04-17, 424B4, 2025-11-06, S-1/A, 2025-10-17, S-1, 2025-10-09; ticker EVMN on New York Stock Exchange.
Keep reading
More on Evommune, Inc. and the records around it.
Evommune, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Andera Partners also filed stake reports on 2 other companies: Inventiva S.A. (Oct 2026), MINERALYS THERAPEUTICS, INC. (Aug 2025)
- Nan Fung Group Holdings Limited also filed stake reports on 2 other companies: Bolt Biotherapeutics, Inc. (Feb 2026), Oculis Holding AG (Nov 2025)
- LSP 7 Cooperatieve U.A. also filed stake reports on 3 other companies: Electra Therapeutics, Inc. (Sep 2026), Oculis Holding AG (Apr 2026), AgomAb Therapeutics NV (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/evommune